Clinical-stage biopharmaceutical company Clene Inc. announced proof-of-concept evidence of potential neuroprotective effects of CNM-Au8, an oral therapeutic for patients with stable relapsing-remitting MS.
According to a release from Clene, data from the VISIONARY-MS trial were presented at the 14th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis Nov. 24 to 26 in Singapore.
The phase 2, randomized, double-blind, placebo-controlled trial included patients with stable relapsing-remitting MS and chronic optic neuropathy. Participants received 15 or 30 mg per